133 related articles for article (PubMed ID: 12402428)
1. [Low-dose cisplatin and UFT for hormone refractory prostate cancer].
Hoshi S; Ohyama C; Namiki S; Hagisawa S; Satoh M; Saito S; Ono K; Shirasaka T; Arai Y
Gan To Kagaku Ryoho; 2002 Oct; 29(10):1773-8. PubMed ID: 12402428
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of cisplatin, epirubicin, UFT, and leucovorin (PELUF) as first-line chemotherapy in metastatic gastric cancer.
Idelevich E; Karminsky N; Dinerman M; Katsenelson RL; Zvi NB; Baruch NB; Biran H; Man S; Shani A
Acta Oncol; 2007; 46(3):324-9. PubMed ID: 17450467
[TBL] [Abstract][Full Text] [Related]
3. Lycopene: a novel drug therapy in hormone refractory metastatic prostate cancer.
Ansari MS; Gupta NP
Urol Oncol; 2004; 22(5):415-20. PubMed ID: 15464923
[TBL] [Abstract][Full Text] [Related]
4. A phase II study of epirubicin, cisplatin and uracil-tegafur for advanced gastric carcinoma.
Woo IS; Moon DH; Shim BY; Lee MA; Byun JH; Kim KW; Kang JH; Choi MG; Chung IS; Hong YS; Park SY; Lee KS
Jpn J Clin Oncol; 2005 Jan; 35(1):13-7. PubMed ID: 15681598
[TBL] [Abstract][Full Text] [Related]
5. [Chemo-endocrine therapy with low-dose cisplatin, UFT, and dexamethasone for hormone-refractory prostate cancer patients].
Kawaguchi T; Mayama I; Iwabuchi I; Ogasawara M; Tsukui A
Gan To Kagaku Ryoho; 2010 Oct; 37(10):1921-5. PubMed ID: 20948257
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of oral uracil/tegafur plus leucovorin in patients with hormone-refractory prostate carcinoma.
Bhandari MS; Pienta KJ; Fardig J; Olson K; Smith DC
Cancer; 2006 Apr; 106(8):1715-21. PubMed ID: 16534795
[TBL] [Abstract][Full Text] [Related]
7. Complete regression of bone metastases on super bone scan, by low-dose cisplatin, UFT, diethylstilbestrol diphosphate, and dexamethasone in a patient with hormone-refractory prostate cancer.
Hoshi S; Ohyama C; Hagisawa S; Ono K; Satoh M; Saito S; Fukuzaki A; Arai Y
Int J Clin Oncol; 2003 Apr; 8(2):118-20. PubMed ID: 12720106
[TBL] [Abstract][Full Text] [Related]
8. Combination chemotherapy with Tegafur. Uracil (UFT), etoposide, adriamycin and cisplatinum (UFT-EAP) for advanced gastric cancer.
Hayakawa M; Morise K; Chin K; Sugihara M; Morooka Y; Maeda H; Hattori T; Saito H
Jpn J Clin Oncol; 1994 Oct; 24(5):282-8. PubMed ID: 7967107
[TBL] [Abstract][Full Text] [Related]
9. Oral combination of cyclophosphamide, uracil plus tegafur and estramustine for hormone-refractory prostate cancer.
Nishimura K; Nonomura N; Ono Y; Nozawa M; Fukui T; Harada Y; Imazu T; Takaha N; Sugao H; Miki T; Okuyama A
Oncology; 2001; 60(1):49-54. PubMed ID: 11150908
[TBL] [Abstract][Full Text] [Related]
10. Clinical outcome of oral uracil/tegafur (UFT) therapy for patients with hormone refractory prostate cancer.
Miyake H; Hara I; Yamazaki H; Eto H
Oncol Rep; 2005 Sep; 14(3):673-6. PubMed ID: 16077973
[TBL] [Abstract][Full Text] [Related]
11. [Three cases of metastatic breast cancer, resistant to pre-chemo and/or endocrine therapy, markedly improved with UFT and cyclophosphamide oral combination therapy].
Ogawa Y; Ishikawa T; Ogisawa K; Ikeda K; Nagatsuka I; Matsumura Y; Takashima T; Yashiro M; Onoda N; Nakata B; Kato Y; Hirakawa K
Gan To Kagaku Ryoho; 2000 Nov; 27(13):2123-7. PubMed ID: 11103246
[TBL] [Abstract][Full Text] [Related]
12. A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil.
Hsu CH; Cheng AL; Hsu C; Yang CH; Lu YS; Lin CC; Bu CF; Yeh KH
Anticancer Res; 2002; 22(6B):3621-7. PubMed ID: 12552966
[TBL] [Abstract][Full Text] [Related]
13. [Case of stage IVb gastric cancer in which favorable anti-tumor effect and good QOL were observed due to UFTP therapy after low-dose CDDP-tegafur therapy].
Takai S; Taki S; Fujino R; Oshita M; Otsuka T; Hirose Y; Sumitomo M; Hayashi N; Nagano T; Matsumura M
Gan To Kagaku Ryoho; 1999 Nov; 26(13):2077-80. PubMed ID: 10584575
[TBL] [Abstract][Full Text] [Related]
14. Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111.
Hussain M; Tangen CM; Lara PN; Vaishampayan UN; Petrylak DP; Colevas AD; Sakr WA; Crawford ED;
J Clin Oncol; 2005 Dec; 23(34):8724-9. PubMed ID: 16314632
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of the MDR inhibitor Incel (biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone-refractory prostate cancer.
Rago RP; Einstein A; Lush R; Beer TM; Ko YJ; Henner WD; Bubley G; Merica EA; Garg V; Ette E; Harding MW; Dalton WS
Cancer Chemother Pharmacol; 2003 Apr; 51(4):297-305. PubMed ID: 12721757
[TBL] [Abstract][Full Text] [Related]
16. [Combination therapy with estrogen and UFT in newly diagnosed prostatic cancer (poorly differentiated, stage D2)].
Kondo I; Miura T; Fujii H; Harada M; Fukushima S; Kubota Y; Hosaka M
Hinyokika Kiyo; 1996 Mar; 42(3):201-6. PubMed ID: 8619389
[TBL] [Abstract][Full Text] [Related]
17. Diethylstilbestrol and docetaxel: a Phase II study of tubulin active agents in patients with metastatic, androgen-independent prostate cancer.
Montgomery RB; Nelson PS; Lin D; Ryan CW; Garzotto M; Beer TM
Cancer; 2007 Sep; 110(5):996-1002. PubMed ID: 17639587
[TBL] [Abstract][Full Text] [Related]
18. Activity of weekly paclitaxel in advanced hormone-refractory prostate cancer.
Chiappino I; Destefanis P; Addeo A; Galetto A; Cucchiarale G; Munoz F; Zitella A; Ferrando U; Fontana D; Ricardi U; Tizzani A; Bertetto O
Am J Clin Oncol; 2007 Jun; 30(3):234-8. PubMed ID: 17551298
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of low-dose paclitaxel and cisplatin in patients with advanced gastric cancer.
Lee KW; Im SA; Yun T; Song EK; Na Ii; Shin H; Choi IS; Oh DY; Kim JH; Kim DW; Kim TY; Lee JS; Heo DS; Bang YJ; Kim NK
Jpn J Clin Oncol; 2005 Dec; 35(12):720-6. PubMed ID: 16332718
[TBL] [Abstract][Full Text] [Related]
20. [A case of rectal cancer with lymph node metastasis (N4) successfully treated with low-dose cisplatin and UFT].
Futagami F; Konishi I; Ninomiya I
Gan To Kagaku Ryoho; 1999 Sep; 26(10):1491-4. PubMed ID: 10500541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
